...
首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
【24h】

Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression

机译:I型干扰素抑制肿瘤内CCL22抑制调节性T细胞迁移并阻止癌症进展

获取原文
获取原文并翻译 | 示例

摘要

The chemokine CCL22 is abundantly expressed in many types of cancer and is instrumental for intratumoral recruitment of regulatory T cells (Treg), an important subset of immunosuppressive and tumor-promoting lymphocytes. In this study, we offer evidence for a generalized strategy to blunt Treg activity that can limit immune escape and promote tumor rejection. Activation of innate immunity with Toll-like receptor (TLR) or RIG-I-like receptor (RLR) ligands prevented accumulation of Treg in tumors by blocking their immigration. Mechanistic investigations indicated that Treg blockade was a consequence of reduced intratumoral CCL22 levels caused by type I IFN. Notably, stable expression of CCL22 abrogated the antitumor effects of treatment with RLR or TLR ligands. Taken together, our findings argue that type I IFN blocks the Treg-attracting chemokine CCL22 and thus helps limit the recruitment of Treg to tumors, a finding with implications for cancer immunotherapy. (C) 2015 AACR.
机译:趋化因子CCL22在多种类型的癌症中大量表达,并在肿瘤内募集调节性T细胞(Treg),这是免疫抑制和促进肿瘤的淋巴细胞的重要子集。在这项研究中,我们为钝化Treg活性的通用策略提供了证据,该策略可限制免疫逃逸并促进肿瘤排斥。用Toll样受体(TLR)或RIG-1样受体(RLR)配体激活先天免疫,通过阻止Treg在肿瘤中的迁移而阻止了Treg的积累。机理研究表明,Treg阻断是由I型IFN引起的肿瘤内CCL22水平降低的结果。值得注意的是,CCL22的稳定表达消除了RLR或TLR配体治疗的抗肿瘤作用。综上所述,我们的研究结果认为,I型干扰素可阻断吸引Treg的趋化因子CCL22,从而有助于限制Treg在肿瘤中的募集,这一发现对癌症免疫疗法具有重要意义。 (C)2015 AACR。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号